Insights

Additional insights

Speaking engagements

  • “The Patent Trial and Appeal Board,” House Judiciary Committee Staff (Dem) (2022)
  • “APJ Day: Strategic Considerations for Advancing Your AIA Trial Position Through Conference Calls with the PTAB,” PTAB Bar Association Annual Conference, Washington, D.C. (2022)
  • “A View From the Bench – The Perspective of PTAB Judges,” Momentum Events 10th National Strategy Summit on Paragraph IV Litigation (2021)
  • “Legal Experience and Advancement Program,” AIPLA-PTAB Bench & Bar (2021)
  • “The APJs Speak on Practice, Policy and Procedure,” American Conference Institute 12th Summit on Biosimilars & Innovator Biologics (2021)
  • “Appeals,” Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting (2021)
  • “Fast-Track Appeals Pilot Program,” PTAB Boardside Chat Webinar (2021)
  • “PTAB Stats and Substance: Questions and Controversies Surrounding Filings, Judicial Appointments, Standing and Expanded Powers,” American Conference Institute 14th Annual Paragraph IV Disputes (2020)
  • “PTAB Practice, Policy and Procedure,” American Conference Institute 11th Summit on Biosimilars & Innovator Biologics, (2020)
  • “Influential Women in IP,” World Intellectual Property Review (WIPR), Tysons Corner, VA (2019)
  • “PTAB: Hot Topics & The Intersection With District Court Litigation,” Delaware Chapter of the Federal Bar Association, Patent Trial & Appeal Board CLE, Wilmington, DE (2018)
  • “PTAB Practice and Impact of Recent Federal Circuit Decisions,” 12th Annual Advanced Patent Law Institute, Alexandria, VA (2017)
  • “Obviousness in PTAB Trials for Chem/Pharma/Bio Patents—How Strong Is Your Case?” World Intellectual Property Review (WIPR) (2016)
  • “Claim Definiteness,” 11th Annual Advanced Patent Law Institute, Alexandria, VA (2016)
  • “Exploring Inter-Partes Review and Covered Business Method Proceedings: IPR/CBM Procedures, Pitfalls and Strategies From Petition Through Appeal,” Los Angeles Intellectual Property Law Association (LAIPLA) “Washington in the West” Program (2016)
  • “Written Description & Enablement in Biotechnology & Pharmaceutical Cases,” USPTO-TIPO (Taiwan Intellectual Property Office) Examiner Exchange Program (2015)
  • “Claim Definiteness,” 10th Annual Advanced Patent Law Institute, Alexandria, VA (2015)
  • “Standard for Indefiniteness,” Bloomberg BNA Conference, Washington, D.C. (2014)
  • “Nautilus v. Biosig Instruments: Where Does the Definiteness Requirement Go From Here?” AIPLA Webinar (2014)
  • “A Discussion of Nautilus v. Biosig,” Federal Circuit Bar Association (FCBA) Webcast (2014)
  • “Written Description for Antibodies,” AIPLA Annual Meeting, Washington, D.C. (2012)
  • “The Written Description Requirement: Are Antibodies Chemicals, Proteins, or Exceptions?," American Bar Association (ABA) (2012)

Media mentions